1 / 35

Problems with multi-resistant Acinetobacter spp .

Problems with multi-resistant Acinetobacter spp . Kevin Towner Dept. of Clinical Microbiology Nottingham University Hospitals NHS Trust. Members of the genus Acinetobacter are now recognised as significant nosocomial pathogens.

betty_james
Télécharger la présentation

Problems with multi-resistant Acinetobacter spp .

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Problems with multi-resistant Acinetobacter spp. Kevin Towner Dept. of Clinical Microbiology Nottingham University Hospitals NHS Trust

  2. Members of the genus Acinetobacter are now recognised as significant nosocomial pathogens • Critically-ill patients requiring mechanical ventilation in ICUs • Wound infections (trauma patients) • Community-acquired infections (usually in patients with co-morbidities, with most reports from tropical or sub-tropical areas)

  3. Which Acinetobacter? • Modern molecular-based taxonomy recognises at least 33 different genomic groups • 18 of these have species names • A further 28 groups have been identified that contain multiple strains, and there are at least 21 ungrouped single strains

  4. Three major overlapping populations • Hospitals and hospitalised patients ‘multi-resistant’ isolates A. baumannii, sp.3, sp.13TU (particularly adapted to this environment?) • Skin (humans and animals) / foodstuffs ‘sensitive’ isolates A. johnsonii, A. lwoffii, A. radioresistens • Soil / environment / wastewaters ‘sensitive’ isolates A. calcoaceticus, A. johnsonii Natural habitats of other species still poorly defined

  5. Problems in the hospital setting since 1976 • Persistence resistant to drying and disinfectants • Antibiotic resistance increasing proportion of isolates are multi-resistant (including carbapenems) remarkable ability to acquire resistance genes • Causes outbreaks

  6. A Typical ICU Problem • 41% (77/189) carriage of a multi-resistant isolate amongst ICU patients • 71% of these were colonised in the first week on ICU • Of those colonised in the first week, 26% (vs. 5%) developed clinically significant infection Corbella et al. (1996) Clinical Infectious Diseases 23:329.

  7. Where is the ‘reservoir’ for nosocomial infection with Acinetobacter baumannii ? • Patients admitted from the community? • Patients admitted from other hospitals? • Within the hospital itself?

  8. Hands of staff Ventilators Humidifiers Oxygen analysers Respirometers Bronchoscopes Lotion dispensers Bed frames Rubbish bins Sinks Air supply Jugs Bowls Soap Hand cream Plastic screens Bed linen Service ducts /dust Bedside charts Patients Hospital sources

  9. Survival of Acinetobacter in the environment • Survives in dry particles and dust for up to 10 days (7 days for S. aureus) • Encapsulated strains survive for >4 months on PVC, ceramics, rubber, steel • Survives exposure to chlorhexidine, gluconate and phenol-based disinfectants • Survives exposure to radiation

  10. What’s the problem with Acinetobacter? • Epidemic spread among patients in hospitals, particularly in ICUs • Patients disseminate large numbers of organisms into their environment • Survival on numerous surfaces and inanimate objects • Resistant to drying and disinfectants • Difficult to eradicate

  11. How does Acinetobacter compare with MRSA in terms of epidemiology? • in individual hospitals? • on a global scale?

  12. Typing methods for Acinetobacter • RAPD is useful for same-day typing of isolates at the local level

  13. LUH 7020 LUH 6609 LUH 6571 LUH 6547 LUH 6488 LUH 6940 LUH 6946 LUH 6947 LUH 6948 LUH 6949-1 LUH 6949-2 LUH 7020 LUH 6609 LUH 6571 LUH 6547 LUH 6488 LUH 6940 LUH 6946 LUH 6947 LUH 6948 LUH 6949-1 LUH 6949-2 M13 DAF4 M M M M 600 bp 300 bp 100 bp RAPD-PCR with primers M13 and DAF4 J Clin Microbiol 35: 3071-3077

  14. Typing methods for Acinetobacter • RAPD is useful for same-day typing of isolates at the local level • PFGE using ApaI is still the typing standard used by most central reference laboratories (3-5 days)

  15. Examples of PFGE gels using ApaI

  16. Typing methods for Acinetobacter • RAPD is useful for same-day typing of isolates at the local level • PFGE using ApaI is still the typing standard used by most central reference laboratories (3-5 days) • Automated AFLP analysis on a DNA sequencer provides good results for archiving in databases (5 days)

  17. AFLP for typing Acinetobacter • DNA preparation according to Boom method • Restriction (EcoRI and MseI) and ligation adaptors • Amplification with a labelled primer • Cy-5 labelled fragment separation on an automated • sequencer • Analysis by BioNumerics • 3 widespread ‘European clones’ (lineages) have been • identified using AFLP

  18. ~85% Grouping of 31 A. baumannii isolates (L. Dijkshoorn, ENEMTI Study, 2002)

  19. Typing methods for Acinetobacter • RAPD is useful for same-day typing of isolates at the local level • PFGE using ApaI is still the typing standard used by most central reference laboratories (3-5 days) • Automated AFLP analysis on a DNA sequencer provides good results for archiving in databases (5 days) • Sequence-based typing (MLST, PCR-based sequence typing)– produces clusters equivalent to those obtained using PFGE

  20. PCR-based sequence typing • based on sequence analysis of three genes from strains in clusters identified by PFGE • uses two multiplex PCRs with primers targeting different sequences of the 3 genes • ompA • csuE • blaOXA-51-like (Turton et al., 7th International Symposium on the Biology of Acinetobacter, 2006; Clin Microbiol Infect, in press)

  21. PCR-based sequence typing (rapid form of MLST for local use)

  22. Developing epidemiology of A. baumannii in the UK • A survey in 1999-2001 identified 34 different RAPD genotypes in 46 UK hospitals • These were shown to belong to 10 different AFLP clusters • In general, particular strains were characteristic of particular hospitals (J Clin Microbiol 42: 832-834)

  23. Between 2003 and 2006, two carbapenem-resistant A. baumannii lineages (SE clone and OXA-23 clone) became prevalent in over 40 hospitals each; susceptible only to colistin and tigecycline (J Clin Microbiol 44: 3623-3627) • More recently, a further lineage (the Northwest strain) has become prevalent in several hospitals in the northern/midlands of the UK

  24. Are specific carbapenem-resistant clones spreading in European hospitals? • As part of the ARPAC project, 169 hospitals in 32 countries provided data concerning multiresistant isolates of Acinetobacter spp. • 130 reported encountering carbapenem-resistant isolates of Acinetobacter, ranging from rare sporadic isolates to an endemic/epidemic situation

  25. Diverse clusters identified by RAPD, PFGE and PCR-based sequence typing in European hospitals (more than just 2 or 3 clones!) • As in the UK, multiple isolates from a single hospital generally belonged to the same clone (some exceptions)

  26. Isolates belonging to sequence group 1 (European ‘clone II’ lineage) found in hospitals in Czech Republic, Germany, Greece, Italy, Poland, Spain, UK (and Argentina and Taiwan!) • Isolates belonging to sequence group 2 (European ‘clone I’ lineage) found in hospitals in Bulgaria, Croatia, Germany, Greece, The Netherlands, Norway, Poland, Slovenia (and Argentina and Taiwan!) • Isolates belonging to sequence group 3 (European ‘clone III lineage) found in France, Germany, The Netherlands and Spain • At least 14 other lineages identified in European hospitals and worldwide

  27. Acinetobacter baumannii has become a major cause of hospital-acquired infections because of its remarkable ability to survive and spread in the hospital environment and to rapidly acquire resistance determinants to a wide range of antibacterial agents • Are we seeing worldwide spread of multiresistant lineages selected primarily on the basis of the resistance genes that they carry? • Or is there something special about certain lineages that confers epidemic potential?

  28. Acinetobacter – the Gram-negative MRSA?How does the epidemiology stack-up? • it infects the ill • it is multidrug-resistant • it prolongs hospitalisation • it causes outbreaks • it persists • multiple isolates from the same hospital usually belong to the same clone • particular epidemic lineages are spreading globally

  29. So what’s special about Acinetobacter? • Perhaps by accident, it has evolved a range of its own special resistance genes (particularly carbapenemases) and the capacity to over-express them in response to antibiotic challenge • A range of expression mechanisms (provision of promoters on insertion sequences) enables ‘foreign’ resistance genes to be expressed

  30. What’s really special about Acinetobacter? • It has evolved molecular mechanisms to capture (and express) resistance genes from other organisms • Sequence analysis of a multiresistant strain, combined with comparative genomics, has revealed an 86-kb ‘resistance island’ which contains a cluster of 45 different resistance genes PLoS Genet 2(1): e7 • (analogous to SCCmec)

  31. Largest resistance island identified to date • Contains 88 predicted ORFs, with 45 identified resistance genes (including 19 putative resistance genes not previously described in Acinetobacter) and 22 ORFs encoding transposases or mobility associated proteins (? 39 ORFs from Pseudomonas spp., 30 from Salmonella spp., 15 from E. coli) • Includes three class I integrons, two operons associated with heavy metal resistance, and genes encoding efflux pumps • Analysis of a ‘sensitive’ isolate revealed a 20-kb ‘island’ devoid of resistance markers, but with mobility associated genes

  32. What treatment options remain?(may be useful in individual patients, but resistance has already appeared) • Polymyxin (colistin) • Sulbactam combinations • Rifampicin/amikacin combinations • Tigecycline • Synthetic peptides (in development)

  33. Acinetobacter baumannii has become a major cause of hospital-acquired infections because of its remarkable ability to survive and spread in the hospital environment and to rapidly acquire resistance determinants to a wide range of antibacterial agents It is the ability to ‘switch’ its genomic structure, combined with variable gene expression, that probably explains the unmatched speed at which A. baumannii can respond to selection pressure from antimicrobial agents, and the main reason why outbreaks caused by this organism are rapidly becoming unmanageable

More Related